The trial population will consist of patients with LAVC who require primary chemoradiation or extensive surgery damaging pelvic organs or exenterative surgery.
Conditions
Brief summary
The primary endpoint is loco‐regional control at 2 years per arm, including salvage or adjuvant treatments
Detailed description
Morbidity, Disease-related treatment failure, Disease-free survival, Prevention of trimodal treatment (surgery and chemotherapy and radiotherapy), functional organ preservation, Quality of life, Treatment-related morbidity, death, Complications, Influence of HPV status on treatment outcome
Interventions
DRUGCISPLATIN
DRUGCARBOPLATIN
DRUGPACLITAXEL
Sponsors
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is loco‐regional control at 2 years per arm, including salvage or adjuvant treatments | — |
Secondary
| Measure | Time frame |
|---|---|
| Morbidity, Disease-related treatment failure, Disease-free survival, Prevention of trimodal treatment (surgery and chemotherapy and radiotherapy), functional organ preservation, Quality of life, Treatment-related morbidity, death, Complications, Influence of HPV status on treatment outcome | — |
Countries
Belgium, Czechia, Netherlands, Spain
Outcome results
None listed